| Engineering antigen‐specific NK cell lines against the melanoma‐associated antigen tyrosinase via TCR gene transfer A Parlar, EC Sayitoglu, D Ozkazanc, AM Georgoudaki, C Pamukcu, ... European journal of immunology 49 (8), 1278-1290, 2019 | 41 | 2019 |
| Fractionated charge variants of biosimilars: A review of separation methods, structural and functional analysis M Yüce, F Sert, M Torabfam, A Parlar, B Gürel, N Çakır, DE Dağlıkoca, ... Analytica chimica acta 1152, 238189, 2021 | 22 | 2021 |
| Influence of Fluid Properties on Intensity of Hydrodynamic Cavitation and Deactivation of Salmonella typhimurium MT Gevari, A Parlar, M Torabfam, A Koşar, M Yüce, M Ghorbani Processes 8 (3), 326, 2020 | 18 | 2020 |
| Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy G Kara, A Parlar, MC Cakmak, M Cokol, EB Denkbas, F Bakan Colloids and Surfaces B: Biointerfaces 196, 111340, 2020 | 17 | 2020 |
| SELEX against whole-cell bacteria resulted in lipopolysaccharide binding aptamers D Yılmaz, T Muslu, A Parlar, H Kurt, M Yüce Journal of Biotechnology 354, 10-20, 2022 | 10 | 2022 |
| Optimized methods for analytical and functional comparison of biosimilar mAb drugs: A case study for Avastin, Mvasi, and Zirabev B Gürel, E Çapkın, A Parlar, A Özkan, M Çorbacıoğlu, DE Dağlikoca, ... Scientia Pharmaceutica 90 (2), 36, 2022 | 8 | 2022 |
| Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study B Gurel, M Berksoz, E Capkin, A Parlar, MC Pala, A Ozkan, Y Capan, ... Pharmaceutics 14 (8), 1571, 2022 | 4 | 2022 |
| Analytical investigation of forced oxidized anti-VEGF IgG molecules: a focus on the alterations in antigen and receptor binding activities A Parlar, B Gurel, MR Sönmez, M Yüce Scientia Pharmaceutica 91 (3), 31, 2023 | | 2023 |
| Characterization of structural and functional properties of anti-VEGF-IgG molecules under certain environmental stress conditions A Parlar | | 2021 |
| Characterization of Biological Molecule—Loaded Nanostructures Using Circular Dichroism and Fourier Transform Infrared Spectroscopy A Parlar, PK Kulabhusan, H Kurt, B Gürel, M Torabfam, B Özata, M Yüce Drug Delivery with Targeted Nanoparticles, 131-146, 2021 | | 2021 |
| Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer. A Parlar, EC Sayitoglu, C Pamukcu, AM Georgoudaki, D Ozkazanc, ... CANCER IMMUNOLOGY RESEARCH 8 (4), 49-50, 2020 | | 2020 |
| Abstract A21: Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer A Parlar, EC Sayitoglu, C Pamukcu, AM Georgoudaki, D Ozkazanc, ... Cancer Immunology Research 8 (4_Supplement), A21-A21, 2020 | | 2020 |
| Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells EC Sayitoglu, D Ozkazanc, A Sarac, A Parlar, E Alici, B Erman, AD Duru, ... The Journal of Immunology 200 (1_Supplement), 169.19-169.19, 2018 | | 2018 |
| A novel approach in cancer immunotherapy: natural killer cells expressing T cell receptors A Parlar | | 2017 |
| Engineering antigen-specific NK cells via TCR gene transfer: a novel source for adoptive immunotherapy A Parlar, C Pamukcu, D Özkazanç, M Aras, C Dahlberg, M Chrobok, ... Mary Ann Liebert 28 (12), A31-A32, 2017 | | 2017 |
| Enhancing lentiviral gene delivery to human natural killer cells for applications in cancer immunotherapy. EC Sayitoglu, D Ozkazanc, A Parlar, A Sarac, B Erman, M Chrobok, ... Turkish Journal of Immunology 4, 2016 | | 2016 |
| The anti-tumor activity of natural killer cell-derived exosomes. E Doğan, A Parlar, EC Sayitoğlu, T Sütlü, B Erman, AD Duru Turkish Journal of Immunology 4, 2016 | | 2016 |
